608
mAbexperimental
Year 608 (DCVIII) was a leap year starting on Monday of the Julian calendar. The denomination 608 for this year has been used since the early medieval period, when the Anno Domini calendar era became the prevalent method in Europe for naming years. — Wikipedia
Clinical trial activity
7 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
6
Phase 3
3
Phase 4
0
Earliest trial started Nov 25, 2019 (NCT04367441)
Timeline
Indications
Mechanism of action
- Interleukin 17AINHIBITOR
IL17A inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- Wikipedia608 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07261644 | Phase 3 | Nov 7, 2025 | Sunshine Lake Pharma Co., Ltd. |
| NCT06299982 | Phase 3 | May 15, 2024 | Sunshine Lake Pharma Co., Ltd. |
| NCT06242652 | Phase 2 | Mar 19, 2024 | Sunshine Lake Pharma Co., Ltd. |
| NCT06222671 | Phase 2 | Jan 31, 2024 | Chinese Academy of Medical Sciences, Sunshine Lake Pharma Co., Ltd. |
| NCT05536726 | Phase 3 | Dec 31, 2022 | Fudan University, Sunshine Lake Pharma Co., Ltd. |
| NCT05604898 | Phase 2 | Apr 1, 2021 | Fudan University, Sunshine Lake Pharma Co., Ltd. |
| NCT04367441 | Phase 1 | Nov 25, 2019 | Sunshine Lake Pharma Co., Ltd. |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sunshine Lake Pharma Co., Ltd. | For profit | 7 | 7 | 3 | 2019 |
| Fudan University | Academic/Hospital | 2 | 0 | 2 | 2021 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2024 |
3 organizations
Page 1 / 1